Lenvatinib Submitted to FDA for Thyroid Cancer Approval
the Cancer Therapy Advisor take:
Eisai has filed a new drug application with the U.S. Food and Drug Administration (FDA) for lenvatinib for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer. Lenvatinib was granted orphan drug status by the FDA in February 2013.
The new drug application filing is based on the phase 3 double-blind, randomized, placebo-controlled SELECT study, which showed that lenvatinib delayed disease progression by 18.3 months compared with 3.6 months in the placebo group. In addition, 65% of patients taking lenvatinib experienced partial responses and 2% attained a complete response.
The study also found that lenvatinib caused several adverse effects, including hypertension, diarrhea, fatigue, decreased appetite, nausea, and vomiting.
Lenvatinib is a tyrosine kinase inhibitor that targets VEGFR1-3, FGFR1-4, PDGFR-β, KIT, and RET. If approved, lenvatinib would most likely be administered orally once daily as a 24 mg dose to patients whose differentiated thyroid cancer is 131I-refractory or -resistant following external beam radiotherapy or radiofrequency ablation.
Another targeted tyrosine kinase inhibitor, sorafenib, was approved by the FDA in November 2013 for radioiodine-resistant differentiated thyroid cancer.
Lenvatinib has been submitted as a treatment for progressive thyroid cancer.
Eisai has filed its anticancer agent lenvatinib with regulators on both sides of the Atlantic. Specifically the drug has been submitted as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer.
The filings, which come after a Japanese submission in June, is based on a 392-patient Phase III study which showed that lenvatinib achieved a statistically significant improvement in progression-free survival.
Related Links Eisai's lenvatinib to get speedy review in Europe Lenvatinib has orphan drug designation for thyroid cancer in the USA, Japan and in Europe, where it has granted an accelerated assessment by the European Medicines Agency, as a new medicine expected to be of major public health interest.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models